Alivus Life Sciences to Attend Emkay Confluence Investor Meet on Aug 12, 2026
Alivus Life Sciences Limited will attend the Emkay Confluence investor meet on August 12, 2026, in Mumbai. The meeting will consist of group and one-on-one interactions. The company has notified exchanges as per SEBI regulations.
This is a routine disclosure about an investor meet, which is a standard practice for listed companies and is unlikely to have a significant impact on the company's stock price or business operations.
The announcement is a routine disclosure about an upcoming investor meeting and does not contain any new financial or business performance information, hence it is neutral.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its participation in an Investor/Analyst meet. The meeting is scheduled to take place on August 12, 2026, in Mumbai. Representatives of the company will be attending the Emkay Confluence conference, which will involve group and one-on-one interactions.
The company has informed the stock exchanges, BSE Ltd. and National Stock Exchange of India Ltd., about this engagement, as per Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The mode and schedule of the meeting are subject to change based on exigencies from the investor, analyst, or the company.
Rudalf Corriea, Company Secretary & Compliance Officer, has signed the disclosure on behalf of Alivus Life Sciences Limited.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.